Clinical trial
Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With…
NCT00393809 · Hebrew University of Jerusalem, Other · Completed
Key facts
| NCT number | NCT00393809 |
|---|---|
| Title | Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer |
| Official title | Phase 1/2a, Dose-Escalation, Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer |
| Lead sponsor | Hebrew University of Jerusalem, Other |
| Collaborators | Anchiano Therapeutics Israel Ltd. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Neoplasms |
| Intervention type | Drug |
| Interventions | DTA-H19 |
| Enrollment | 18 |
| Start date | Jan 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Oct 30, 2006 |
| Last update posted | Jan 7, 2008 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: